Medidata vs Unlearn.AI (2026)
The platform that holds the trial against the method that changes how many patients it needs. Medidata's capabilities sit on infrastructure spanning tens of thousands of studies with the most complete security disclosure in this index, so for a sponsor already running it the AI arrives inside a validated environment. Unlearn generates digital twins of trial participants, forecasting how each would have progressed under control and using that as a covariate to reduce enrolment requirements, with method transparency approaching an academic standard and a regulatory achievement distinct from and arguably harder than a device clearance. They are complementary. Unlearn changes the protocol; Medidata runs whatever protocol you land on, and Unlearn's evidence is statistical efficiency rather than patient outcomes.
- Its capabilities sit on a clinical trial platform spanning tens of thousands of studies and millions of patients, with the most complete security disclosure in this index.
- For a sponsor already running the platform, capability arrives inside an environment that is already validated.
- Breadth across the lifecycle from study start through regulatory submission covers more than one phase of work.
- Its method transparency approaches an academic standard, with the procedure published and the statistical properties described rather than asserted.
- The regulatory achievement is distinct from and arguably harder than a device clearance, and it is unique in this index.
- The autonomy question is solved by design rather than by policy, which is the most rigorous answer to it recorded here.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Medidata and Unlearn.AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Medidata | Unlearn.AI |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2017 |
| Headquarters | New York, New York | San Francisco, California, United States |
| Website | medidata.com | unlearn.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Medidata its top capability grade on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and EHR and Interoperability Depth. Set against Unlearn.AI, Medidata grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Unlearn.AI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Medidata, Unlearn.AI grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Medidata or Unlearn.AI?
On the axes where the AI Health Index separates them, Medidata grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture, and Unlearn.AI grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Medidata leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Medidata and Unlearn.AI differ most?
The widest separation the AI Health Index records between Medidata and Unlearn.AI is on Security Certifications and Trust Center, where Medidata grades A and Unlearn.AI grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Medidata and Unlearn.AI grade the same?
The AI Health Index grades Medidata and Unlearn.AI the same on Clinical and Operational Evidence, FDA and Regulatory Status and Commercial Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Medidata and Unlearn.AI not disclosed?
At the last review, at least one of Medidata and Unlearn.AI published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These operate at different points, one changing the statistical design of a trial before it runs and the other holding and processing the data once it does, so they are complementary and a large sponsor will have both. Unlearn's evidence measures statistical efficiency rather than patient outcomes, which is the right claim for what it does and should not be read as clinical benefit. Medidata's AI capabilities are named rather than described with no published oversight design. Neither publishes pricing, and both should be asked whether one sponsor's data informs models serving another.